Editorial
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastrointest Oncol. Jul 15, 2013; 5(7): 113-114
Published online Jul 15, 2013. doi: 10.4251/wjgo.v5.i7.113
Hilar cholangiocarcinoma
José M Ramia
José M Ramia, Department of Surgery, Hospital Universitario de Guadalajara, 19002 Guadalajara, Spain
Author contributions: Ramia JM solely contributed to this paper.
Correspondence to: José M Ramia, MD, PhD, Department of Surgery, Hospital Universitario de Guadalajara, Donante de Sangre, S/N, 19002 Guadalajara, Spain. jose_ramia@hotmail.com
Telephone: +34-61-6292056 Fax: +34-94-9209218
Received: March 11, 2013
Revised: June 16, 2013
Accepted: July 4, 2013
Published online: July 15, 2013
Abstract

Hilar cholangiocarcinoma (HC) is a rare tumor. It accounts for 2/3 of the tumors of the biliary tract. Untreated, prognosis is very poor. Surgery is the only therapy that offers the possibility of cure but is technically very complex. With recent improvements in the therapeutic strategies applied by multidisciplinary teams, survival rates in the different series currently range from 25% to 45%. A group of experts devoted to HC (pathologists, gastroenterologists, radiologists, surgeons and oncologists) have reviewed and updated every open question in HC in a special issue.

Keywords: Cholangiocarcinoma, Hilar, Perihilar, Klatskin, Surgery, Cancer, Review

Core tip: Most remarked avances are: imaging methods have improved diagnostic sensitivity and specificity, especially for determining biliary and vascular involvement; there have been several proposals to improve the classic Bismuth-Corlette classification; pre- and post-operative care; technical aspects trying to obtain a R0 resection: widespread use of liver resection, resection of segment I and venous and arterial resection, refinement of post-operative histology and adjuvant therapies.